Skip to main content

Comparison of a bronchoscopic microsample probe with bronchoalveolar lavage to measure cytokine levels in critically ill patients


The use of bronchoalveolar lavage (BAL) to investigate inflammatory lung disease in the critically ill may not be tolerated in hypoxic patients. Furthermore, soluble protein analysis of BAL fluid suffers from inaccuracies related to saline dilution. The bronchoscopic microsample (BMS) probe allows absolute cytokine levels in epithelial lining fluid (ELF) to be measured directly without lavage [1]. We compared cytokine levels from ELF obtained by the BMS probe with those from BAL, to verify its utility in critical illness.


We recruited 45 patients into five groups in whom BMS and BAL were conducted sequentially: two ventilated with ALI/ARDS, six with burns inhalational injury (five ventilated), 15 with COPD, 18 with interstitial lung disease and four healthy patients. The BMS probe was bronchoscopically inserted to the subsegmental level in order to contact the mucosa for 5 to 7 seconds, collecting approximately 20 μl ELF [1]. BAL was performed with 150 ml of 0.9% saline, discarding the first 20 ml (bronchiolar fraction). We assayed IL-1, IL-6, IL-8, TNFα and G-CSF. Comparisons between paired cytokine ELF concentrations in BMS and BAL were analysed using the nonparametric Wilcoxon's test and Spearman's correlation coefficient.


The critically ill patients were aged 18 to 84 years (APACHE II 12 to 21). One patient had ARDS due to urinary tract infection and another related to pneumonia. No adverse incidents noted were noted. Overall, cytokine levels were all higher in the BMS group than BAL (P < 0.0001), consistent with ELF dilution by saline lavage. The ratio of BMS-derived cytokine to BAL for each patient group did not differ significantly. Spearman coefficients (r) for IL-1, IL-6, IL-8, TNFα and G-CSF were 0.38, 0.52, 0.25, 0.38 and 0.40. All correlations were significant (P < 0.01) except for IL-8 (P = 0.05). Both sampling methods demonstrated a gradation of cytokine level, with burns and ALI/ARDS having significantly higher levels than patients with stable chronic lung disease or healthy controls.


The BMS probe was well tolerated and provided cytokine data comparable to that obtained by BAL in acute and chronic respiratory diseases. The BMS probe may have utility as a biomarker sampling modality in patients where clinicians have concerns over conventional BAL.


  1. Ishizaka A, et al.: Crit Care Med. 2001, 29: 896-898. 10.1097/00003246-200104000-00043

    CAS  Article  PubMed  Google Scholar 

Download references


The BMS probes were provided by Olympus (Tokyo, Japan).

Author information

Authors and Affiliations


Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Cite this article

Grover, V., Christie, L., Charles, P. et al. Comparison of a bronchoscopic microsample probe with bronchoalveolar lavage to measure cytokine levels in critically ill patients. Crit Care 16, P72 (2012).

Download citation

  • Published:

  • DOI:


  • Interstitial Lung Disease
  • Cytokine Level
  • Epithelial Line Fluid
  • Inhalational Injury
  • Inflammatory Lung Disease